We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
6 peer-reviewed studies
What the evidence says
Most Empagliflozin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2015–2023 with a typical study size of 7,020 participants.
Based on 6 studies · 1 meta-analysis · 4 RCTs · 7,020 total participants
Confidence
ModerateBy outcome
1 study in the last 5 years · Latest meta-analysis: 2016
An SGLT2 inhibitor (empagliflozin) reduced cardiovascular death and all-cause mortality in type 2 diabetes.
Zinman, Wanner, Lachin, Fitchett, Bluhmki, Hantel · The New England journal of medicine (2015)
Empagliflozin improved clinical outcomes in type 2 diabetes patients with established cardiovascular disease.
Wanner, Lachin, Inzucchi, Fitchett, Mattheus, George · Circulation (2018)
Empagliflozin slowed progression of chronic kidney disease across a broad range of patients (EMPA-KIDNEY).
Herrington, Staplin, Wanner, Green, Hauske, Emberson · The New England journal of medicine (2023)
EMPEROR-Reduced showed empagliflozin reduced cardiovascular death or heart-failure hospitalization in heart failure with reduced ejection fraction.
Packer, Anker, Butler, Filippatos, Pocock, Carson · The New England journal of medicine (2020)
Reducing blood pressure and SGLT2-mediated effects improved cardiovascular outcomes and mortality in diabetes.
Scheen · Diabetes research and clinical practice (2016)
EMPEROR-Preserved and related trials position SGLT2 inhibitors as a foundation of heart-failure treatment.
Williams, Evans · Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)